Author

Carlos R. Figueiredo

Åbo Akademi UniversityORCID 0000-0003-3680-4070Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Ábris Ádám BendesiD· 1 shared Arno YlitaloiD· 1 shared Daniel A. PatteniD· 1 shared Eleftheria MaranouiD· 1 shared Ga‐Young ParkiD· 1 shared Ilaria di Benedetto· 1 shared Ilkka KoskivuoiD· 1 shared Jenna H. RannikkoiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Ábris Ádám BendesORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintDec 22, 2025

CD74 regulates antitumor immunity in melanoma by reprogramming dendritic cell immunogenicity and migration

Eleftheria Maranou, Ga‐Young Park, Pauline Weinzettl…·Carlos R. Figueiredo

This study shows CD74 deletion enhances dendritic cell function and tumor immunogenicity in melanoma, improving immune checkpoint therapy outcomes.

DOI 10.64898/2025.12.01.691518

mousebulk RNA-seq

𝕏 PostBluesky

ImmunologyTheranosticsPeer-reviewedJun 23, 2025

Secreted Clever-1 Modulates T Cell Responses and Impacts Cancer Immunotherapy Efficacy

Stuart Prince, Miro Viitala, Riikka Sjöroos…·Maija Hollmén

This study identifies a secreted form of Clever-1 that suppresses T cell responses and reduces anti-PD-1 efficacy in cancer, suggesting it as a therapeutic target and biomarker.

9 citations

humanproteomics

𝕏 PostBluesky